{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-029090","form_type":"8-K","ticker":null,"cik":"0000827871","company_name":"EAGLE PHARMACEUTICALS, INC.","filed_at":"2024-02-29T23:59:59+00:00","discovered_at":"2026-05-14T18:03:27.016210+00:00","generated_at":"2026-06-05T07:37:25.376561+00:00","sec_items":["2.05"],"event_type":"other_material","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Eagle Pharmaceuticals cuts workforce 36% in realignment plan; expects $3.5M cash charges","bullets":["Board approved Realignment Plan reducing workforce ~36%, affecting employees supporting Byfavo, Barhemsys, Ryanodex.","Estimated $3.5M cash charges: $3.1M severance/healthcare, $0.4M retention benefits; recorded in Q1 2024.","Plan substantially complete by end of Q1 2024; company to continue commercialization with reduced team plus oncology sales.","Also performing impairment analysis over certain long-lived assets and inventory; may record non-cash impairment charges."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-029090","json":"https://secwatch.observer/filing/0001104659-24-029090.json","markdown":"https://secwatch.observer/filing/0001104659-24-029090.md","text":"https://secwatch.observer/filing/0001104659-24-029090.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/827871/000110465924029090/0001104659-24-029090-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/827871/000110465924029090/tm247572d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T07:37:25.376561+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"6086956748efa924425c1cd3947400e9c70e75ff","claim":"EAGLE PHARMACEUTICALS, INC. announced a restructuring with charges of approximately $3.5 million in cash charges affecting commercialization of Byfavo, Barhemsys and Ryanodex (approximately 36%).","evidence_excerpt":"expenditures relating to the Realignment Plan will not be known until all related activities have been completed. The Company estimates that it will incur approximately $3.5 million in cash charges in connection with the Realignment Plan, consisting of (i) approximately $3.1 million in cash-based expenses related to employee severance payments and healthcare","evidence_source":"SEC 8-K Item 2.05/2.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/827871/000110465924029090/0001104659-24-029090-index.htm","confidence":0.9,"family_label":"Restructurings & Charges","details":[{"label":"Type","value":"restructuring"},{"label":"Charge","value":"approximately $3.5 million in cash charges"},{"label":"Affected area","value":"commercialization of Byfavo, Barhemsys and Ryanodex"},{"label":"Headcount","value":"approximately 36%"}],"fact_type":"restructuring_charge"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}